Nitrofurantoin Explained

Verifiedfields:verified
Watchedfields:verified
Verifiedrevid:462261865
Width:250px
Alt2:Ball-and-stick model of the nitrofurantoin molecule
Tradename:Macrobid, others[1]
Dailymedid:Nitrofurantoin
Pregnancy Au:A
Routes Of Administration:By mouth
Class:Antibiotic
Atc Prefix:J01
Atc Suffix:XE01
Legal Au:S4
Legal Au Comment:[2]
Legal Ca:Rx-only
Legal Ca Comment:[3] [4]
Legal Uk:POM
Legal Uk Comment:[5]
Legal Us:Rx-only
Legal Us Comment:[6]
Legal Eu:Rx-only
Legal Eu Comment:[7]
Bioavailability:~20–94%[8] [9] [10]
Protein Bound:60–77% (primarily albumin)
Elimination Half-Life:0.33–1.7hours[11]
Excretion:Almost exclusively urine (4–59% over 3–30hours; ~20–25% unchanged) and bile[12]
Cas Number:67-20-9
Pubchem:6604200
Drugbank:DB00698
Chemspiderid:5036498
Unii:927AH8112L
Kegg:D00439
Chebi:71415
Chembl:572
Iupac Name:(E)-1-[(5-nitro-2-furyl)methylideneamino]imidazolidine-2,4-dione
C:8
H:6
N:4
O:5
Smiles:O=[N+]([O-])c2oc(/C=N/N1C(=O)NC(=O)C1)cc2
Stdinchi:1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+
Stdinchikey:NXFQHRVNIOXGAQ-YCRREMRBSA-N
Melting Point:270
Melting High:272
Melting Notes:(decomp.)

Nitrofurantoin, sold under the brand name Macrobid among others, is an antibacterial medication of the nitrofuran class used to treat urinary tract infections (UTIs), although it is not as effective for kidney infections.[13] It is taken by mouth.[13]

Common side effects include nausea, loss of appetite, diarrhea, and headaches.[13] Rarely numbness, lung problems, or liver problems may occur.[13] While it appears to be generally safe during pregnancy its use is not recommended near time of delivery.[13] [14] While it usually works by slowing bacterial growth, it may result in bacterial death at the high concentrations found in urine, provided forced fluid dilution of urine is avoided.[13]

Nitrofurantoin was first sold in 1953.[15] It is on the World Health Organization's List of Essential Medicines.[16] It is available as a generic medication.[13] In 2022, it was the 158th most commonly prescribed medication in the United States, with more than 3million prescriptions.[17] [18]

Medical uses

Urinary tract infections

Uses of nitrofurantoin include the treatment of uncomplicated urinary tract infections (UTIs) and prophylaxis against UTIs in people prone to recurrent UTIs. It is a first-line therapy for acute uncomplicated cystitis. It is not recommended for empiric treatment of hospital-acquired UTIs.

Increasing bacterial antibiotic resistance to other commonly used agents, such as trimethoprim/sulfamethoxazole and fluoroquinolones, has led to increased interest in using nitrofurantoin in the contemporary treatment of UTIs.[19] [20] The efficacy of nitrofurantoin in treating UTIs combined with a low rate of bacterial resistance to this agent makes it one of the first-line agents for treating uncomplicated UTIs as recommended by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.[21]

In meta-analyses of clinical trials, nitrofurantoin has shown clinical UTI cure rates of 79 to 92% and bacterial eradication rates of 80 to 92%.[22] Treatment with nitrofurantoin for 7days was not more effective than treatment for 5days, whereas treatment for 5days was superior to treatment for 3days (which showed clinical cure rates of 61–70%). The effectiveness of nitrofurantoin for 5days is equivalent to that with single-dose fosfomycin.[23]

As a prophylactic against UTIs, nitrofurantoin was similarly effective to other antibiotics, with a UTI risk ratio of 0.38.[24] [25] Taken daily long-term as a prophylactic, there were no differences in effectiveness between different doses of nitrofurantoin (50mg/day, 75mg/day, 100mg/day, or 50mg twice daily). Although similarly effective as other antibiotics, prophylactic nitrofurantoin showed an increased risk of adverse effects compared to other antibiotics (risk ratios = 2.17 to 2.24). The adverse effects of nitrofurantoin were mostly gastrointestinal in nature.

Other bacterial infections

Nitrofurantoin is not recommended for the treatment of pyelonephritis (kidney infection), and intra-abdominal abscess,[26] because of extremely poor tissue penetration and low blood levels.[13]

Nitrofurantoin appears likely to minimally penetrate the prostate gland.[27] [28] [29] As such, nitrofurantoin is not recommended for eradication of chronic bacterial prostatitis.[30] In any case, in men with antibiotic-refractory or relapsing chronic bacterial prostatitis, prophylactic nitrofurantoin may be useful in preventing UTIs and managing symptoms.[31] [32] However, supporting data are lacking as of 2020.

Antibacterial activity

Nitrofurantoin has been shown to have good activity against:[33] [34]

It is used in the treatment of infections caused by these organisms.[35]

Many or all strains of the following genera are resistant to nitrofurantoin:

Special populations

Pregnancy

Nitrofurantoin is pregnancy category A in Australia. It is one of the few drugs commonly used in pregnancy to treat UTIs.[36] There is a potential risk of hemolytic anemia in the newborn when used near time of delivery.[37] Newborns of women given this drug late in pregnancy had a higher risk of developing neonatal jaundice.[38]

Evidence of safety in early pregnancy is mixed as of 2017. The American College of Obstetricians and Gynecologists states that while they can be used in the first trimester other options may be preferred. They remain a first line treatment in the second trimester.[39] A 2015 meta analysis found no increased risk from first trimester use in cohort studies that was a slight increase of malformations in case control studies.[40]

Contraindications

Nitrofurantoin is contraindicated in patients with decreased renal function (CrCl <) due to systemic accumulation and subtherapeutic levels reached in the urinary tract. However, a retrospective chart review suggests the data for this cutoff are slim and a cutoff of CrCl < would be more appropriate.[41] Many of the severe side effects of this drug are more common in the elderly and those with renal impairment, as this causes the drug to be retained in the body and reach higher systemic levels. Thus, the drug is not recommended for the elderly population according to 2012 AGS Beers Criteria.[42]

Nitrofurantoin is also contraindicated in babies up to the age of one month, as they have immature enzyme systems in their red blood cells (glutathione instability), so nitrofurantoin must not be used because it can cause haemolytic anaemia. Nitrofurantoin is contraindicated in patients with glucose-6-phosphate dehydrogenase deficiency (G6PD) because of risk of intravascular hemolysis resulting in anemia.

Adverse effects

The most common side effects of nitrofurantoin are nausea, headache, and flatulence. Less common adverse events (occurring in less than 1% of those taking the drug) include:

Taken daily long-term as a prophylactic, side effects of nitrofurantoin occur at rates of 0 to 29%. They are generally mild, reversible, and are predominantly gastrointestinal.

Lung toxicity

The pulmonary toxicity caused by nitrofurantoin can be categorized into acute, subacute, and chronic pulmonary reactions. The acute and subacute reactions are thought to be due to a hypersensitivity reaction and often resolve when the drug is discontinued. Acute reactions have been estimated to occur in about one in 5000 women who take the drug.[43] These reactions usually develop 3–8 days after the first dose of nitrofurantoin, but may occur from a few hours to a few weeks after starting the drug. Symptoms include fever, dyspnea, chills, cough, pleuritic chest pain, headache, back pain, and epigastric pain. Chest radiograph will often show unilateral or bilateral infiltrates similar to pulmonary edema.[44]

Chronic pulmonary reactions caused by nitrofurantoin include diffuse interstitial pneumonitis, pulmonary fibrosis, or both. This uncommon reaction may occur 1 month to 6 years after starting the drug and is usually related to its total lifetime dose. This reaction manifests with progressive shortness of breath.[45] It is important to recognize nitrofurantoin as possible cause of symptoms and discontinue the drug when the suspicion of pulmonary side effects arises as it can be reversible if the drug is stopped early.

Liver toxicity

Liver reactions, including hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis, occur rarely.[46]

Neuropathy

Neuropathy is a rare side effect of taking nitrofurantoin. Patients may experience numbness and tingling in a stocking-glove pattern, which may or may not improve upon discontinuation of the drug.[47]

Gut microflora

Nitrofurantoin has been found to modify the gut microbiota composition.[48] Effects in three clinical studies have included increased abundance of Actinobacteria, Bifidobacterium species, and Clostridium species, decreased abundance of Faecalibacterium species, and no changes. Similarly to other antibiotics, nitrofurantoin has been associated with increased risk of Clostridioides difficile infection and associated diarrhea.[49] [50] However, this was based on a single study in which only two cases occurred. Other sources state that nitrofurantoin has a low risk of Clostridioides difficile infection.

Interactions

Nitrofurantoin has historically been reported to be a disulfiram-like drug and to produce alcohol intolerance-type reactions when combined with alcohol.[51] However, subsequent clinical studies failed to replicate these findings and the earlier results have been deemed erroneous.

Pharmacology

Organisms are said to be susceptible to nitrofurantoin if their minimum inhibitory concentration is 32 μg/mL or less. The peak blood concentration of nitrofurantoin following an oral dose of nitrofurantoin 100mg is less than 1μg/mL and may be undetectable. Its bioavailability is about 90% and the urinary excretion is 40%[52] tissue penetration is negligible; the drug is well concentrated in the urine: 75% of the dose is rapidly metabolised by the liver, but 25% of the dose is excreted in the urine unchanged, reliably achieving levels of 200μg/mL or more. In studies of dogs, the majority of urinary excretion is through glomerular filtration with some tubular secretion.[53] There is also tubular absorption which is increased with urine acidification. However the activity of nitrofurantoin is also pH dependent and mean inhibitory concentration rises sharply with increased pH above 6. Nitrofurantoin cannot be used to treat infections other than simple cystitis.

At the concentrations achieved in urine (>100μg/mL), nitrofurantoin is a bactericide. It is bacteriostatic against most susceptible organisms at concentrations less than 32μg/mL.

Nitrofurantoin and the quinolone antibiotics are mutually antagonistic in vitro. It is not known whether this is of clinical significance.

Resistance to nitrofurantoin may be chromosomal or plasmid-mediated and involves inhibition of nitrofuran reductase.[54] Acquired resistance in E. coli continues to be rare.

Nitrofurantoin and its metabolites are excreted mainly by the kidneys. In renal impairment, the concentration achieved in urine may be subtherapeutic.[55]

Mechanism of action

Nitrofurantoin is concentrated in the urine, leading to higher and more effective levels in the urinary tract than in other tissues or compartments.[56] With a oral dose, plasma levels are typically less than while in the urine it reaches .[57]

The drug works by damaging bacterial DNA, since its reduced form is highly reactive. This is made possible by the rapid reduction of nitrofurantoin inside the bacterial cell by flavoproteins (nitrofuran reductase) to multiple reactive intermediates that attack ribosomal proteins, DNA,[58] respiration, pyruvate metabolism and other macromolecules within the cell. Nitrofurantoin exerts greater effects on bacterial cells than mammalian cells because bacterial cells activate the drug more rapidly. It is not known which of the actions of nitrofurantoin is primarily responsible for its bactericidal activity. The broad mechanism of action for nitrofurantoin is likely responsible for the low development of resistance to its effects, as it affects many different processes important to the bacterial cell.

History

Nitrofurantoin has been available for the treatment of lower UTIs since 1953.[15]

Society and culture

Brand names

Nitrofurantoin is marketed under many names in countries worldwide.[59]

Animal feed

Residues from the breakdown of nitrofuran veterinary antibiotics, including nitrofurantoin, have been found in chicken in Vietnam, China, Brazil, and Thailand.[60] The European Union prohibited the use of nitrofurans in food producing animals by classifying it in ANNEX IV (list of pharmacologically active substances for which no maximum residue limits can be fixed) of the Council Regulation 2377/90. The Food and Drug Administration (FDA) of the United States has prohibited furaltadone since February 1985 and withdrew the approval for the other nitrofuran drugs (except some topical uses) in January 1992. The topical use of furazolidone and nitrofurazone was prohibited in 2002. Australia prohibited the use of nitrofurans in food production in 1992. Japan did not allocate MRLs for nitrofurans leading to the implementation of a "zero tolerance or no residue standard". In Thailand, the Ministry of Health issued in 2001 Proclamation No. 231 MRL of veterinary drug in food which did not allocate MRL for nitrofurans. The Ministry of Agriculture and Cooperatives had already prohibited importation and use of furazolidone and nitrofurazone in animal feed in 1999 which was extended to all nitrofurans in 2002. Several metabolites of nitrofurans, such as furazolidone, furaltadone and nitrofurazone cause cancer or genetic damage in rats.[60]

Notes and References

  1. Web site: Nitrofurantoin .
  2. Web site: Macrodantin Product Information . TGA eBS . 24 June 2024 . 24 June 2024.
  3. Web site: Macrodantin Product information . . 16 September 1996 . 24 June 2024.
  4. Web site: Macrobid Product information . . 12 August 2021 . 24 June 2024.
  5. Web site: Macrobid Summary of Product Characteristics (SmPC) . (emc) . 14 February 2024 . 24 June 2024.
  6. Web site: Macrobid - nitrofurantoin monohydrate/macrocrystalline capsule . DailyMed . 30 June 2023 . 24 June 2024.
  7. https://www.ema.europa.eu/en/documents/psusa/nitrofurantoin-nifurtoinol-list-nationally-authorised-medicinal-products-psusa00002174202102_en.pdf
  8. Wijma RA, Fransen F, Muller AE, Mouton JW . Optimizing dosing of nitrofurantoin from a PK/PD point of view: What do we need to know? . Drug Resist Updat . 43 . 1–9 . March 2019 . 30947111 . 10.1016/j.drup.2019.03.001 .
  9. Cunha BA . Nitrofurantoin--current concepts . Urology . 32 . 1 . 67–71 . July 1988 . 3291373 . 10.1016/0090-4295(88)90460-8 .
  10. Dos Santos C, Dos Santos LS, Franco OL . Fosfomycin and nitrofurantoin: classic antibiotics and perspectives . J Antibiot (Tokyo) . 74 . 9 . 547–558 . September 2021 . 34244614 . 10.1038/s41429-021-00444-z .
  11. Wijma RA, Huttner A, Koch BC, Mouton JW, Muller AE . Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline . Journal of Antimicrobial Chemotherapy . 73 . 11 . 2916–2926 . November 2018 . 30184207 . 10.1093/jac/dky255 .
  12. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020064Orig1s029lbl.pdf
  13. Web site: Nitrofurantoin. The American Society of Health-System Pharmacists. 1 August 2015. live. https://web.archive.org/web/20150707224038/http://www.drugs.com/monograph/nitrofurantoin.html. 7 July 2015.
  14. Web site: Prescribing medicines in pregnancy database. Australian Government. 22 April 2014. 3 March 2014. live. https://web.archive.org/web/20140408040902/http://www.tga.gov.au/hp/medicines-pregnancy.htm#.U1Yw8Bc3tqw. 8 April 2014.
  15. Book: Blass B . Basic Principles of Drug Discovery and Development . 2015 . Elsevier . 9780124115255 . 511 . live. https://web.archive.org/web/20170908150204/https://books.google.com/books?id=YTvLAwAAQBAJ&pg=PA511 . 8 September 2017.
  16. Book: ((World Health Organization)) . The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) . 2023 . 10665/371090 . World Health Organization . World Health Organization . Geneva . WHO/MHP/HPS/EML/2023.02 . free .
  17. Web site: The Top 300 of 2022 . ClinCalc . 30 August 2024 . 30 August 2024 . https://web.archive.org/web/20240830202410/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  18. Web site: Nitrofurantoin Drug Usage Statistics, United States, 2013 - 2022 . ClinCalc . 30 August 2024 .
  19. Garau J . Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline . Clinical Microbiology and Infection . 14 . Suppl 1 . 198–202 . January 2008 . 18154548 . 10.1111/j.1469-0691.2007.01852.x . free .
  20. McKinnell JA, Stollenwerk NS, Jung CW, Miller LG . Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis . Mayo Clinic Proceedings . 86 . 6 . 480–488 . June 2011 . 21576512 . 3104907 . 10.4065/mcp.2010.0800 .
  21. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE . International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases . Clinical Infectious Diseases . 52 . 5 . e103–e120 . March 2011 . 21292654 . 10.1093/cid/ciq257 . free .
  22. Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW . Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials . J Antimicrob Chemother . 70 . 9 . 2456–2464 . September 2015 . 26066581 . 10.1093/jac/dkv147 .
  23. Konwar M, Gogtay NJ, Ravi R, Thatte UM, Bose D . Evaluation of efficacy and safety of fosfomycin versus nitrofurantoin for the treatment of uncomplicated lower urinary tract infection (UTI) in women - A systematic review and meta-analysis . J Chemother . 34 . 3 . 139–148 . May 2022 . 34151754 . 10.1080/1120009X.2021.1938949 .
  24. Muller AE, Verhaegh EM, Harbarth S, Mouton JW, Huttner A . Nitrofurantoin's efficacy and safety as prophylaxis for urinary tract infections: a systematic review of the literature and meta-analysis of controlled trials . Clin Microbiol Infect . 23 . 6 . 355–362 . June 2017 . 27542332 . 10.1016/j.cmi.2016.08.003 .
  25. Price JR, Guran LA, Gregory WT, McDonagh MS . Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis . Am J Obstet Gynecol . 215 . 5 . 548–560 . November 2016 . 27457111 . 10.1016/j.ajog.2016.07.040 .
  26. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG . Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America . Clinical Infectious Diseases . 50 . 2 . 133–164 . January 2010 . 20034345 . 10.1086/649554 . free .
  27. Su ZT, Zenilman JM, Sfanos KS, Herati AS . Management of Chronic Bacterial Prostatitis . Curr Urol Rep . 21 . 7 . 29 . June 2020 . 32488742 . 10.1007/s11934-020-00978-z .
  28. Lipsky BA, Byren I, Hoey CT . Treatment of bacterial prostatitis . Clin Infect Dis . 50 . 12 . 1641–1652 . June 2010 . 20459324 . 10.1086/652861 . Nitrofurantoin prostatic levels are likely nontherapeutic..
  29. Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N . Penetration of antimicrobial agents into the prostate . Chemotherapy . 49 . 6 . 269–279 . December 2003 . 14671426 . 10.1159/000074526 . Good to excellent penetration into prostatic fluid and tissue has been demonstrated with many antimicrobial agents, including tobramycin, netilmicin, tetracyclines, macrolides, quinolones, sulfonamides and nitrofurantoin. [...] Nitrofurantoin is a lipid-soluble weak acid with a pKa value that is somewhat favorable for diffusion into prostatic fluid [78]. Although low levels of nitrofurantoin were achieved in prostatic fluid in dogs, the administration of standard oral doses of this drug to men results in levels of ≤1 μg/ml of blood; such levels guarantee that the levels attained in prostatic fluid will be nontherapeutic..
  30. Chou A, Welch E, Hunter A, Trautner BW . Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review . Drugs . 82 . 4 . 407–438 . March 2022 . 35286622 . 9057390 . 10.1007/s40265-022-01676-5 . We agree with guidelines [270] recommending fluoroquinolones, trimethoprim, and tetracyclines for treatment of chronic bacterial prostatitis, if the causative organism is susceptible. Emerging pharmacologic and clinical data also support the use of oral fosfomycin 3g every 2 days for 6–12 weeks for treatment of chronic bacterial prostatitis [256, 266, 271]. We avoid prescribing nitrofurantoin due to concerns of poor prostatic concentration [265]..
  31. Bowen DK, Dielubanza E, Schaeffer AJ . Chronic bacterial prostatitis and chronic pelvic pain syndrome . BMJ Clin Evid . 2015 . August 2015 . 26313612 . 4551133 . A third-line option is chronic oral antibiotic suppression to prevent recurrent cystitis. There is the potential for side effects with any medication, thus the risks of chronic antibiotic use (such as tendon damage with quinolones) must be weighed against the potential benefits. However, a chronic suppression approach only mandates adequate drug levels in the urine and does not require penetrance of the prostate, thus many antibiotic choices with a safer side effect profile are available, such as nitrofurantoin and cephalosporins..
  32. Fowler JE . Antimicrobial therapy for bacterial and nonbacterial prostatitis . Urology . 60 . 6 Suppl . 24–6; discussion 26 . December 2002 . 12521585 . 10.1016/s0090-4295(02)02300-2 . The fluoroquinolone antibiotics given for 2 to 4 weeks will cure about 70% of chronic bacterial infections of the prostate. If this treatment fails, the symptomatic manifestations of the infections can almost always be eliminated with suppressive antimicrobial therapy using [...] nitrofurantoin. [...] Reported experiences with chronic bacterial prostatitis indicate that low-dose [...] nitrofurantoin (50 or 100 mg once daily) are remarkably effective.1,8 A large experience with these agents for prophylaxis against frequent urinary tract reinfection in women suggest that indefinite treatment is generally well tolerated.1 [...] Nitrofurantoin macrocrystals, 100 mg twice daily for 7 days is recommended for the initial treatment of suspected chronic bacterial prostatitis [...] Nitrofurantoin macrocrystals will not eradicate bacteria in the prostate and will facilitate the interpretation of subsequent lower tract bacterial localization studies.9.
  33. Mahdizade Ari M, Dashtbin S, Ghasemi F, Shahroodian S, Kiani P, Bafandeh E, Darbandi T, Ghanavati R, Darbandi A . Nitrofurantoin: properties and potential in treatment of urinary tract infection: a narrative review . Front Cell Infect Microbiol . 13 . 1148603 . 2023 . 37577377 . 10.3389/fcimb.2023.1148603 . free . 10414118 .
  34. Bader MS, Loeb M, Leto D, Brooks AA . Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents . Postgrad Med . 132 . 3 . 234–250 . April 2020 . 31608743 . 10.1080/00325481.2019.1680052 .
  35. Gupta K, Scholes D, Stamm WE . Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women . JAMA . 281 . 8 . 736–738 . February 1999 . 10052444 . 10.1001/jama.281.8.736 . free .
  36. Lee M, Bozzo P, Einarson A, Koren G . Urinary tract infections in pregnancy . Canadian Family Physician . 54 . 6 . 853–854 . June 2008 . 18556490 . 2426978 . 4 August 2009 . live . https://web.archive.org/web/20210828185536/https://www.cfp.ca/content/54/6/853.long . 28 August 2021 .
  37. Web site: Nitrofurantoin Use During Pregnancy . Drugs.com . 10 September 2019 . 3 December 2018 . https://web.archive.org/web/20181203125751/https://www.drugs.com/pregnancy/nitrofurantoin.html . live .
  38. Nordeng H, Lupattelli A, Romøren M, Koren G . Neonatal outcomes after gestational exposure to nitrofurantoin . Obstetrics and Gynecology . 121 . 2 Pt 1 . 306–313 . February 2013 . 23344280 . 10.1097/AOG.0b013e31827c5f88 . 25848306 .
  39. Web site: Sulfonamides, Nitrofurantoin, and Risk of Birth Defects - ACOG . www.acog.org . 25 November 2019 . 30 September 2019 . https://web.archive.org/web/20190930010144/https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Sulfonamides-Nitrofurantoin-and-Risk-of-Birth-Defects . live .
  40. Goldberg O, Moretti M, Levy A, Koren G . Exposure to nitrofurantoin during early pregnancy and congenital malformations: a systematic review and meta-analysis . Journal of Obstetrics and Gynaecology Canada . 37 . 2 . 150–156 . February 2015 . 25767948 . 10.1016/S1701-2163(15)30337-6 . free .
  41. Oplinger M, Andrews CO . Nitrofurantoin contraindication in patients with a creatinine clearance below : looking for the evidence . The Annals of Pharmacotherapy . 47 . 1 . 106–111 . January 2013 . 23341159 . 10.1345/aph.1R352 . 28181644 .
  42. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults . Journal of the American Geriatrics Society . 60 . 4 . 616–631 . April 2012 . 22376048 . 3571677 . 10.1111/j.1532-5415.2012.03923.x . American Geriatrics Society 2012 Beers Criteria Update Expert Panel .
  43. Jick SS, Jick H, Walker AM, Hunter JR . Hospitalizations for pulmonary reactions following nitrofurantoin use . Chest . 96 . 3 . 512–515 . September 1989 . 2766810 . 10.1378/chest.96.3.512 .
  44. Williams EM, Triller DM . Recurrent acute nitrofurantoin-induced pulmonary toxicity . Pharmacotherapy . 26 . 5 . 713–718 . May 2006 . 16718946 . 10.1592/phco.26.5.713 . 29563196 .
  45. Goemaere NN, Grijm K, van Hal PT, den Bakker MA . Nitrofurantoin-induced pulmonary fibrosis: a case report . Journal of Medical Case Reports . 2 . 1 . 169 . May 2008 . 18495029 . 2408600 . 10.1186/1752-1947-2-169 . free .
  46. Amit G, Cohen P, Ackerman Z . Nitrofurantoin-induced chronic active hepatitis . The Israel Medical Association Journal . 4 . 3 . 184–186 . March 2002 . 11908259 .
  47. Tan IL, Polydefkis MJ, Ebenezer GJ, Hauer P, McArthur JC . Peripheral nerve toxic effects of nitrofurantoin . Archives of Neurology . 69 . 2 . 265–268 . February 2012 . 22332195 . 10.1001/archneurol.2011.1120 . free .
  48. Zimmermann P, Curtis N . The effect of antibiotics on the composition of the intestinal microbiota - a systematic review . J Infect . 79 . 6 . 471–489 . December 2019 . 31629863 . 10.1016/j.jinf.2019.10.008 .
  49. Bignardi GE . Risk factors for Clostridium difficile infection . J Hosp Infect . 40 . 1 . 1–15 . September 1998 . 9777516 . 10.1016/s0195-6701(98)90019-6 .
  50. Hirschhorn LR, Trnka Y, Onderdonk A, Lee ML, Platt R . Epidemiology of community-acquired Clostridium difficile-associated diarrhea . J Infect Dis . 169 . 1 . 127–133 . January 1994 . 8277174 . 10.1093/infdis/169.1.127 .
  51. Mergenhagen KA, Wattengel BA, Skelly MK, Clark CM, Russo TA . Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions . Antimicrobial Agents and Chemotherapy . 64 . 3 . February 2020 . 31871085 . 10.1128/AAC.02167-19 . 7038249 .
  52. Book: Conklin JD . Pharmacokinetics . The pharmacokinetics of nitrofurantoin and its related bioavailability . Antibiotics and Chemotherapy . 25 . 233–252 . 1978 . 352255 . 10.1159/000401065 . 978-3-8055-2752-1 .
  53. Shah RR, Wade G . Reappraisal of the risk/benefit of nitrofurantoin: review of toxicity and efficacy . Adverse Drug Reactions and Acute Poisoning Reviews . 8 . 4 . 183–201 . 1989 . 2694823 .
  54. McCalla DR, Kaiser C, Green MH . Genetics of nitrofurazone resistance in Escherichia coli . Journal of Bacteriology . 133 . 1 . 10–16 . January 1978 . 338576 . 221970 . 10.1128/JB.133.1.10-16.1978 .
  55. Bains A, Buna D, Hoag NA . A retrospective review assessing the efficacy and safety of nitrofurantoin in renal impairment . Canadian Pharmacists Journal. 2009. 142. 248–252. 10.3821/1913-701X-142.5.248 . 5 . 56795699 .
  56. Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW . Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials . The Journal of Antimicrobial Chemotherapy . 70 . 9 . 2456–2464 . September 2015 . 26066581 . 10.1093/jac/dkv147 . free .
  57. Book: Basic Principles of Drug Discovery and Development. Blass B . 9780124115255. 513. 24 April 2015. Elsevier .
  58. Tu Y, McCalla DR . Effect of activated nitrofurans on DNA . Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis . 402 . 2 . 142–149 . August 1975 . 1100114 . 10.1016/0005-2787(75)90032-5 .
  59. Web site: Nitrofurantoin . drugs.com . https://web.archive.org/web/20150518093529/http://www.drugs.com/international/nitrofurantoin.html . 18 May 2015 . 2 May 2015 .
  60. Web site: Joint FAO/WHO Technical Workshop on Residues of Veterinary Drugs without ADI/MRL - Bangkok, 24 – 26 August 2004. https://web.archive.org/web/20081204032125/http://www.fao.org/docrep/008/y5723e/y5723e0u.htm. dead. 4 December 2008. www.fao.org.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nitrofurantoin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.